Healthcare News Hubb
  • Home
  • Health Care
  • Public Health
  • Men’s Health
  • Women’s Health
  • Children’s Health
  • Health Insurance
  • Contact
No Result
View All Result
  • Home
  • Health Care
  • Public Health
  • Men’s Health
  • Women’s Health
  • Children’s Health
  • Health Insurance
  • Contact
No Result
View All Result
HealthNews
No Result
View All Result
Home Health Care

Judge halts FDA approval of abortion pill mifepristone

healthcare by healthcare
April 8, 2023
in Health Care
Judge halts FDA approval of abortion pill mifepristone


A federal judge in Texas on Friday ordered a hold on the U.S. approval of the abortion medication mifepristone, throwing into question access to the nation’s most common method of abortion in a ruling that waved aside decades of scientific approval.

The abortion drug has been widely used in the U.S. since 2000 and there is essentially no precedent for a lone judge overruling the medical decisions of the Food and Drug Administration. Mifepristone is one of two drugs used for medication abortion in the United States, along with misoprostol, which is used to treat other medical conditions.

U.S. District Judge Matthew J. Kacsmaryk, a Trump administration appointee in Amarillo, Texas, signed an injunction directing the FDA to stay mifepristone’s approval while a lawsuit challenging the safety and approval of the drug continues. But the immediate impact of the ruling was unclear.

He didn’t go as far as the plaintiffs wanted by withdrawing or suspending the approvals of chemical abortion drugs and removing them from the list of approved drugs. But he put a “stay” or hold on approval of the drug. His ruling, however, doesn’t immediately go into effect.

Kacsmaryk gave the government seven days to appeal.

Federal lawyers representing the FDA are expected to swiftly appeal.

Mifepristone is part of a two-drug regimen that has long been the standard for medication abortion in the U.S. Clinics and doctors that prescribe the combination say they plan to switch to using only misoprostol. The single-drug approach is slightly less effective at ending pregnancies.

The lawsuit was filed by the Alliance Defending Freedom, which was also involved in the Mississippi case that led to Roe v. Wade being overturned. At the core of the lawsuit is the allegation that the FDA’s initial approval of mifepristone was flawed because it did not adequately review its safety risks.

Courts have long deferred to the FDA on issues of drug safety and effectiveness. But the agency’s authority faces new challenges in a post-Roe legal environment in which abortions are banned or unavailable in 14 states, while 16 states have laws specifically targeting abortion medications.



Source link

Previous Post

Interview with Journalism and Media Managing Editor

Next Post

Soft and Chewy Iced Oatmeal Cookies

Next Post
Soft and Chewy Iced Oatmeal Cookies

Soft and Chewy Iced Oatmeal Cookies

Recent Posts

Ideas for The Future of Peer Review
Public Health

Ideas for The Future of Peer Review

by healthcare
September 28, 2023
0

MDPI’s Peer Review Week 2023 Webinar joins the global celebration of peer review and its crucial role in academic publishing....

Read more
Study Finds How Much Fishing Benefits Men’s Mental Health
Men's Health

Study Finds How Much Fishing Benefits Men’s Mental Health

by healthcare
September 28, 2023
0

Research conducted in the U.K. found what longtime fishing hobbyists could have likely already told us. Angling is tied to...

Read more
Non-Smoking Women Can Get Lung Cancer
Women's Health

Non-Smoking Women Can Get Lung Cancer

by healthcare
September 28, 2023
0

Nicole Pajer Nicole Pajer is a freelance writer published in The New York Times, Parade, AARP, Woman's Day, Men's Journal...

Read more
How to Build an Effective HR Strategy without an HR Department
Health Insurance

How to Build an Effective HR Strategy without an HR Department

by healthcare
September 28, 2023
0

In the fast-paced world of modern business, the dynamics of managing human resources can be challenging, especially for small to...

Read more

©  Healthcare News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Health Care
  • Public Health
  • Men’s Health
  • Women’s Health
  • Children’s Health
  • Health Insurance
  • Contact

Newsletter Sign Up.

Loading
No Result
View All Result
  • Home
  • Health Care
  • Public Health
  • Men’s Health
  • Women’s Health
  • Children’s Health
  • Health Insurance
  • Contact

© 2022 HealthCare News Hubb All rights reserved.